Last updated: February 16, 2026
Ertugliflozin, marketed under the brand name Steglatro by Pfizer, is a sodium-glucose co-transporter 2 (SGLT2) inhibitor approved for type 2 diabetes management. Its market position hinges on competitive dynamics within the SGLT2 inhibitor space, patent expiration timelines, and evolving clinical guidelines.
Product Overview
- Approval Date: December 2017 by the FDA
- Indication: Improve glycemic control in adults with type 2 diabetes
- Mechanism: Blocks SGLT2 in kidneys to promote glucose excretion
- Formulation: Oral tablets (5 mg, 15 mg)
Market Landscape
- The SGLT2 inhibitor class includes drugs such as empagliflozin (Jardiance), canagliflozin (Invokana), and dapagliflozin (Farxiga).
- Ertugliflozin's sales peaked at ~$400 million in 2021.
- As of 2022, the drug ranks fourth among SGLT2 inhibitors in multiple markets, following Jardiance, Invokana, and Farxiga.
- The average wholesale price (AWP) in the U.S. ranges from $500 to $600 per month per patient.
Market Drivers
- Rising prevalence of type 2 diabetes — expected to reach 700 million globally by 2045 (IDF).
- Increasing adoption of SGLT2 inhibitors for heart failure and chronic kidney disease, expanding core indications.
- Guidelines from ADA (American Diabetes Association) endorse SGLT2 inhibitors for patients with cardiovascular or renal comorbidities.
Market Challenges
- Competition from entrenched brands (Jardiance, Farxiga) with broader indications.
- Patent exclusivity expiring in key markets:
- U.S.: Patent protecting ertugliflozin expires in 2028
- Europe: Patent clearance anticipated in 2029
- Generic entry expected post-expiry could reduce prices 50% or more, impacting revenue.
Financial Trajectory
- Pfizer’s revenue from Steglatro increased 15% year-over-year until 2021.
- Contribution to Pfizer's diabetes segment remains modest, representing approximately 4% of total revenue.
- Operating margins are expected to decline post-generic entry, with potential erosion of profits starting around 2028.
Forecast Scenarios
- Scenario A (Conservative): Patent expiration in 2028, generic competition reduces sales to 25% of peak levels by 2030.
- Scenario B (Aggressive): Accelerated uptake of combination therapies and expanded indications sustains sales through 2028, with a quick decline afterward.
- Scenario C (Strategic Diversification): Pfizer leverages formulation improvements and new indications, delaying generic impact.
Regulatory and Patent Strategies
- Pfizer has pursued patent extension tactics via method of use claims and formulation patents.
- Patent defenses extend exclusivity to 2028–2029.
- Ongoing litigation in some jurisdictions aims to prolong market protection.
Global Market Considerations
- U.S. accounts for roughly 60% of ertrugliflozin revenues.
- Emerging markets present growth opportunities but face pricing pressures and regulatory hurdles.
- Local reimbursement policies significantly influence revenue potential.
Investment Outlook
- Short-term: Steglatro maintains growth driven by diabetes management needs.
- Medium-term: Sales plateau as patent expiry nears.
- Long-term: Revenue decline expected post-2028, unless Pfizer introduces next-generation formulations or expands indications.
Key Takeaways
- Ertugliflozin holds a significant position within the SGLT2 class but faces imminent patent expiry and generic competition.
- Pfizer's continued profitability depends on successfully extending patent protections and expanding uses.
- Market growth driven by a global increase in diabetes prevalence may offset some revenue loss but unlikely to fully compensate for patent attrition.
- Strategic investments in formulation innovations and expansion into new indications could alter the forecast trajectory.
Frequently Asked Questions
-
When will generic ertugliflozin become available?
Patent expiration in the U.S. is projected for 2028, with patent challenges and litigation possibly influencing the exact timeline.
-
What are the main competitors?
Jardiance (empagliflozin), Invokana (canagliflozin), and Farxiga (dapagliflozin).
-
How does the patent strategy influence revenue?
Patent protections delay generic entry, maintaining pricing power and revenue levels.
-
Could new indications extend its market viability?
Yes, especially if label expansions include heart failure or chronic kidney disease for diverse patient groups.
-
What regulatory risks exist?
Patent challenges, label restrictions, or withdrawal due to safety concerns could impact market access.
References
[1] IQVIA, "Pharmaceutical Market Data," 2022.
[2] FDA, "Ertugliflozin (Steglatro) Approval Letter," December 2017.
[3] International Diabetes Federation, "Diabetes Atlas," 2022.
[4] Pfizer Annual Reports 2021-2022.
